Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates

REFERENCES

• Aghajanian G K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978; 276: 186–188
   PubMed Web of Science ®Google Scholar
• Ahlenius S, Carlsson A, Engel J, Svensson T, Sodersten P. Antagonism by alpha methyltyrosine of the ethanol-induced stimulation and euphoria in man. Clin Pharmacol Ther 1973; 14: 586–591
   PubMed Web of Science ®Google Scholar
• Anton R F, O'Malley S S, Ciraulo D A, Cisler R A, Couper D, Donovan D M, Gastfriend D R, Hosking J D, Johnson B A, Locastro J S, Longabaugh R, Mason B J, Mattson M E, Miller W R, Pettinati H M, Randall C L, Swift R, Weiss R D, Williams L D, Zweben A, Group C SR. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295: 2003–2017
   PubMed Web of Science ®Google Scholar
• Arias A, Feinn R, Kranzler H R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 2006; 83: 262–268
   PubMed Web of Science ®Google Scholar
• Babor T F, Hofmann M, Del Boca F K, Hesselbrock V, Meyer R E, Dolinsky Z S, Rounsaville B. Types of alcoholics, Evidence I. for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599–608
   PubMed Web of Science ®Google Scholar
• Baler R D, Volkow N D. Drug addiction: The neurobiology of disrupted self-control. Trends Mol Medicine 2006; 12: 559–566
   PubMed Web of Science ®Google Scholar
• Barr C S, Schwandt M, Lindell S G, Chen S A, Goldman D, Suomi S J, Higley J D, Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 2007; 64: 369–376
   PubMed Web of Science ®Google Scholar
• Bart G, Kreek M J, Ott J, La Forge K S, Proudnikov D, Pollak L, Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005; 30: 417–422
   PubMed Web of Science ®Google Scholar
• Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability?. Neuropsychopharmacology 1997; 16: 77–82
   PubMed Web of Science ®Google Scholar
• Bearden C E, Freimer N B. Endophenotypes for psychiatric disorders: ready for primetime?. Trends Genet 2006; 22: 306–613
   PubMed Web of Science ®Google Scholar
• Befort K, Filliol D, decaillot F M, Gaveriaux-Ruff C, Hoehe M R, Kieffer B L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001; 276: 3130–3137
   PubMed Web of Science ®Google Scholar
• Berger S P, Winhusen T M, Somoza E C, Harrer J M, Mezinskis J P, Leiderman D B, Montgomery M A, Goldsmith R J, Bloch D A, Singal B M, Elkashef A. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005; 100: 58–67
   PubMed Web of Science ®Google Scholar
• Berrettini W H. Genetic bases for endophenotypes in psychiatric disorders. Dialogues Clin Neurosci 2005; 7: 95–101
   PubMedGoogle Scholar
• Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89: 553–560
   PubMed Web of Science ®Google Scholar
• Bohman M, Sigvardsson S, Cloninger C R, vonknorring A L. Alcoholism: lessons from population, family and adoption studies. Alcohol Alcohol Suppl 1987; 1: 55–60
   PubMedGoogle Scholar
• Bond C, La Forge K S, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong J A, Leal S M, Tischfield J A, Kreek M J, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95: 9608–9613
   PubMed Web of Science ®Google Scholar
• Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. Clin Pharmacol Ther 2008
   PubMed Web of Science ®Google Scholar
• Carlezon W A, Duman R S, Nestler E J. The many faces of CREB. Trends Neurosci 2005; 28: 436–445
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt T E, Taylor A, Craig I W, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389
   PubMed Web of Science ®Google Scholar
• Childress A R, Mozley P D, McElgin W, Fitzgerald J, Reivich M, O'Brien C P. Limbic activation during cue-induced craving. Am J Psychiatry 1999; 156: 11–18
   PubMed Web of Science ®Google Scholar
• Chong R Y, Oswald L M, Yang X, Uhart M, Lin P I, Wand G S. The Micro-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006; 31: 204–211
   PubMed Web of Science ®Google Scholar
• Chou W Y, Wang C H, Liu P H, Liu C C, Tseng C C, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105: 334–337
   PubMed Web of Science ®Google Scholar
• Cloninger C R. The dynamics of social learning. Science 1981; 213: 858–859
   PubMedGoogle Scholar
• Coller J K, Barratt D T, Dahlen K, Loennechen M H, Somogyi A A. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Drug Alcohol Depend 2006; 80: 682–690
   Google Scholar
• Compton W M, Volkow N D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; S4–S7, Suppl 1
   PubMed Web of Science ®Google Scholar
• Crettol S, Déglon J J, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap C B. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668–681
   PubMed Web of Science ®Google Scholar
• deLeon J, Armstrong S C, Cozza K L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 2006; 47: 75–85
   PubMed Web of Science ®Google Scholar
• DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274–5278
   PubMed Web of Science ®Google Scholar
• DiChiara G, North R A. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185–193
   PubMed Web of Science ®Google Scholar
• Dole V P, Nyswander M E. Rehabilitation of heroin addicts after blockade with methadone. NY State J Med 1966; 66: 2011–2017
   PubMedGoogle Scholar
• Drakenberg K, Nikoshkov A, Horváth M C, Fagergren P, Gharibyan A, Saarelainen K, Rahman S, Nylander I, Bakalkin G, Rajs J, Keller E, Hurd Y L. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A 2006; 103: 7883–7888
   PubMed Web of Science ®Google Scholar
• Drolet B, Simard C, Mizoue L, Roden D M. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest 2005; 115
   PubMed Web of Science ®Google Scholar
• Everitt B J, Cardinal R N, Parkinson J A, Robbins T W. Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning. Ann NY Acad Sci 2003; 985: 233–250
   PubMed Web of Science ®Google Scholar
• Everitt B J, Robbins T W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005; 8: 1481–1489
   PubMed Web of Science ®Google Scholar
• Fillingim R B, Kaplan L, Staud R, Ness T J, Glover T L, Campbell C M, Mogil J S, Wallace M R. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005; 6: 159–167
   PubMed Web of Science ®Google Scholar
• Fischman M W, Schuster C R. Cocaine self-administration in humans. Fed Proc 1982; 41: 241–246
   PubMedGoogle Scholar
• Franke P, Wang T, Nöthen M M, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet 2001; 105: 114–119
   PubMed Web of Science ®Google Scholar
• Froehlich J C, Harts J, Lumeng L, Li T K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 1990; 35: 385–390
   PubMed Web of Science ®Google Scholar
• Gabbay F H. Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol 2003; 11: 91–101
   PubMed Web of Science ®Google Scholar
• Gawin F H, Kleber H D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986; 43: 107–113
   PubMed Web of Science ®Google Scholar
• Gelernter J, Kranzler H R, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol-and drug-dependent subjects. Mol Psychiatry 1999; 4: 476–483
   PubMed Web of Science ®Google Scholar
• Ghozland S, Chu K, Kieffer B L, Roberts A J. Lack of stimulant and anxiolytic-like effects of ethanol and accelerated development of ethanol dependence in mu-opioid receptor knockout mice. Neuropharmacology 2005; 49: 493–501
   PubMed Web of Science ®Google Scholar
• Giacomini K M, Brett C M, Altman R B, Benowitz N L, Dolan M E, Flockhart D A, Johnson J A, Hayes D F, Kelein T, Krauss R M, Kroetz D L, McLeod H L, Nguyen A T, Ratain M J, Relling M V, Reuss V, Roden D M, Schaefer C A, Shuldiner A R, Skaar T, Tantisira K TRF, Wang L, Weinshilboum R M, Weiss S T, Zineh I, Network P R. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81: 328–345
   PubMed Web of Science ®Google Scholar
• Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphine to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53: 250–257
   PubMed Web of Science ®Google Scholar
• Goetz M P, Rae J M, Suman V J, Safgren S L, Ames M M, Visscher D W, Reynolds C, Couch F J, Lingle W L, Flockhart D A, Desta Z, Perez E A, Ingle J N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of eficacy and hot flashes. J Clin Oncol 2005; 23: 9312–8
   PubMed Web of Science ®Google Scholar
• Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005; 6: 521–532
   PubMed Web of Science ®Google Scholar
• Goldstein R Z, Volkow N D, Chang L, Wang G J, Fowler J S, Depue R A, Gur R C. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 59: 1642–52
   Web of Science ®Google Scholar
• Gottesmann I I, Gould T D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636–645
   PubMed Web of Science ®Google Scholar
• Gupta S, Jain S, Brahmachari S K, Kukreti R. Pharmacogenetics: a path to predictive medicine for schizophrenia. Pharmacogenomics 2006; 7
   PubMed Web of Science ®Google Scholar
• Gurbel P A, Bliden K P, Hiatt B L, O'Connor C M. Clopidogrel for coronary stenting: reponsive variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107
   PubMed Web of Science ®Google Scholar
• Haile C N, Kosten T A. Differential effects of D1-and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. J Pharmacol Exp Ther 2001; 299: 509–518
   PubMed Web of Science ®Google Scholar
• Haile C N, Kosten T R, Kosten T A. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet 2007; 37: 119–145
   PubMed Web of Science ®Google Scholar
• Hart C L, Ward A S, Haney M, Foltin R W, Fischman M W. Methamphetamine self-administration by humans. Psychopharmacology 2001; 157: 75–81
   PubMed Web of Science ®Google Scholar
• Heffner T G, Hartman J A, Seiden L S. Feeding increases dopamine metabolism in the rat brain. Science 1980; 208: 1168–1170
   PubMed Web of Science ®Google Scholar
• Heinz A, Dettling M, Kuhn S, Dufeu P, Gräf K J, Kürten I, Rommelspacher H, Schmidt I G. Blunted growth hormone response is associated with early relapse in alcohol-dependent patients. Alcohol Clin Exp Res 1995; 19: 62–65
   PubMed Web of Science ®Google Scholar
• Hernandez-Avila C A, Wand G, Luo X, Gelernter J, Kranzler H R. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118: 60–65
   Web of Science ®Google Scholar
• Hesselink D A, van Schaik R H, van der Heiden I P, van der Werf M, Gregoor P J, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–254
   PubMed Web of Science ®Google Scholar
• Hoehe M R, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd K K, Berrettini W H, Church G M. Sequence variability and candidate gene analysis in complex disease: association of mu opioid gene variation with substance dependence. Hum Mol Genet 2000; 9: 2895–2908
   PubMed Web of Science ®Google Scholar
• Holleman A, Cheok M H, Den Boer M L, Yang W, Veerman A J, Kazemier K M, Pei D, Cheng C, Pui C H, Relling M V, Janka-Schaub G E, Pieters R, Evans W E. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and reponse to treatment. N Engl J Med 2004; 351: 601–603
   PubMed Web of Science ®Google Scholar
• Hubbell C L, Czirr S A, Hunter G A, Beaman C M, Lecann N C, Reid L D. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986; 3: 39–54
   PubMed Web of Science ®Google Scholar
• Hyman S E. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162: 1414–1422
   PubMed Web of Science ®Google Scholar
• Hyman S E, Malenka R C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2: 695–703
   PubMed Web of Science ®Google Scholar
• Inturrisi C E, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13: 923–930
   PubMed Web of Science ®Google Scholar
• Jaffe A J, Rounsaville B, Chang G, Schottenfeld R S, Meyer R E, O'Malley S S. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64: 1044–1053
   PubMed Web of Science ®Google Scholar
• Johnson J A. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003; 19: 660–666
   PubMed Web of Science ®Google Scholar
• Johnson S M, Fleming W W. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 1989; 41: 435–488
   PubMed Web of Science ®Google Scholar
• Johnson S W, North R A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12: 483–488
   PubMed Web of Science ®Google Scholar
• Kalivas P W. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004; 4: 23–29
   PubMed Web of Science ®Google Scholar
• Kelley A E, Berridge K C. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22: 3306–3311
   PubMed Web of Science ®Google Scholar
• Kieffer B L, Befort K, Gaveriaux-Ruff C, Hirth C G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 1992; 89: 12048–12052
   PubMed Web of Science ®Google Scholar
• Kim S G, Kim C M, Kang D H, Kim Y J, Byun W T, Kim S Y, Park J M, Kim M J, Oslin D W. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res 2004; 28: 986–990
   PubMed Web of Science ®Google Scholar
• King A C, Volpicelli J R, Frazer A, O'Brien C P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997; 129: 15–22
   PubMed Web of Science ®Google Scholar
• Kling M A, Carson R E, Borg L, Zametkin A, Matochik J A, Schluger J, Herscovitch P, Rice K C, Ho A, Eckelman W C, Kreek M J. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000; 295: 1070–1076
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto T, Chiba K MT, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26: 818–821
   PubMed Web of Science ®Google Scholar
• Koob G F, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97–129
   PubMed Web of Science ®Google Scholar
• Koob G F, Le Moal M. Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci 2005; 8: 1442–1444
   PubMed Web of Science ®Google Scholar
• Kosten TRDAF, Program., U.S.N.B.I. Buprenorphine for office-based practice: consensus conference overview. Am J Addict 2004; 13: S1–S7
   PubMed Web of Science ®Google Scholar
• Kosten T R, Kleber H D. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 1988; 42: 635–641
   PubMed Web of Science ®Google Scholar
• Kosten T R, Morgan C, Kosten T A. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat 1990; 7: 51–54
   PubMed Web of Science ®Google Scholar
• Kosten T R, Morgan C, Kosten T A. Treatment of heroin addicts using buprenorphine. H Am J Drug Alcohol Abuse 1991; 17: 119–128
   PubMed Web of Science ®Google Scholar
• Kreek M J. Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. NY State J Med 1973; 73: 2773–2777
   PubMedGoogle Scholar
• Kreek M J. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. Neurochem Res 1996; 21: 1469–1488
   PubMed Web of Science ®Google Scholar
• Kreek M J, Bart G, Lilly C, La Forge K S, Nielsen D A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57
   Web of Science ®Google Scholar
• Kreek M J, Nielsen D A, Butelman E R, La Forge K S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neuroscience 2005; 8: 1450–1457
   PubMed Web of Science ®Google Scholar
• Kreek M J, Vocci F J. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23: 93–105
   PubMed Web of Science ®Google Scholar
• Kroslak T, La Forge K S, Gianotti R J, Ho A, Nielsen D A, Kreek M J. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77–87
   PubMed Web of Science ®Google Scholar
• Laje G, Paddock S, Manji H, Rush A J, Wilson A F, Charney D, McMahon F J. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164: 1530–1538
   PubMed Web of Science ®Google Scholar
• Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 117–164
   PubMed Web of Science ®Google Scholar
• Lamba J K, Lin Y S, Thummel K, Daly A, Watkins P B, Strom S, Zhang J, Schuetz E G. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–132
   PubMedGoogle Scholar
• Lappalainen J, Long J C, Eggert M, Ozaki N, Robin R W, Brown G L, Naukkarinen H, Virkkunen M, Linnoila M, Goldman D. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry 1998; 55: 989–994
   PubMed Web of Science ®Google Scholar
• Laruelle M, Abi-Dargham A, Van Dyck C H, Rosenblatt W, Zea-Ponce Y, Zonghbi S S, Baldwin R M, Charney D S, Hoffer P B, Kung H F, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36: 1182–1190
   PubMed Web of Science ®Google Scholar
• Lee M C, Wagner H NJ, Tanada S, Frost J J, Bice A N, Dannals R F. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29: 1207–1211
   PubMed Web of Science ®Google Scholar
• Lewohl J M, Wilson W R, Mayfield R D, Brozowski S J, Morrisett R A, Harris R A. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci 1999; 2: 1084–1090
   PubMed Web of Science ®Google Scholar
• Long J C, Knowler W C, Hanson R L, Robin R W, Urbanek M, Moore E, Bennett P H, Goldman D. Evidence for genetic linkage to alcohol dependence on chromosomes 4 and 11 from an autosome-wide scan in an American Indian population. Am J Med Genet 1998; 81: 216–221
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effects of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3–9
   PubMedGoogle Scholar
• Lukas S, Mendelson J. Behavioral concomitants of ethanol and drug reinforcement. NIDA Res Monogr 1988; 81: 422–427
   PubMedGoogle Scholar
• Luo X, Kranzler H R, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in Eurpopean-Americans. Am J Med Genet B Neuropsychiatr Genet 2003; 132: 97–108
   Web of Science ®Google Scholar
• MacGregor A J, Griffiths G O, Baker J, Spector T. Determinants of pressure pain threshold in adult twins: evidence that shared environmental influences predominate. Pain 1997; 73: 253–257
   PubMed Web of Science ®Google Scholar
• Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder J S, Teitelbaum R, Karaskov T, Aleksa K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53: 33–35
   PubMed Web of Science ®Google Scholar
• Maldonado R, Saiardi A, Valverde O, Samad T A, Roques B P, Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997; 388: 586–589
   PubMed Web of Science ®Google Scholar
• Malhotra A K, Murphy G MJ, Kennedy J L. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780–796
   PubMed Web of Science ®Google Scholar
• Mannelli P, Peindl K, Masand P S, Patkar A A. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother 2007; 7: 1265–1277
   PubMedGoogle Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with inicreased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171–3175
   PubMed Web of Science ®Google Scholar
• Matthes H W, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Lemeur M, Dolle P, Tzavara E, Hanoune J, Roques B P, Kieffer B L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid receptor gene. Nature 1996; 383: 819–823
   PubMed Web of Science ®Google Scholar
• Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.H. Cochrane Database Syst Rev 2004; 3
   Google Scholar
• Mayer P, Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006; 16: 1–7
   PubMed Web of Science ®Google Scholar
• McCaul M E, Wand G S, Eissenberg T, Rohde C A, Cheskin L J. Naltrexone alters subjective and psychomotor reponses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22: 480–492
   PubMed Web of Science ®Google Scholar
• McCaul M E, Wand G S, Stauffer R, Lee S M, Rohde C A. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 2001; 25: 537–547
   PubMed Web of Science ®Google Scholar
• Minami M, Hosoi Y, Toya T, Katao Y, Maekawa K, Katsumata S, Yabuuchi K, Onogi T, Satoh M. In situ hybridization study of kappa-opioid receptor mRNA in the rat brain. Neurosci Lett 1993; 162: 161–164
   PubMed Web of Science ®Google Scholar
• Mogil J S, Ritchie J, Smith S B, Strasburg K, Kaplan L, Wallace M R, Romberg R RH, Sarton B. EY, Fillingim R, Dahan A. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42: 583–587
   PubMed Web of Science ®Google Scholar
• Monterosso J R, Flannery B A, Pettinati H M, Oslin D W, Rukstalis M, O'Brien C P, Volpicelli J R. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10: 258–268
   PubMed Web of Science ®Google Scholar
• Murphy G MJ, Kremer C, Rodrigues H E, Schatzberg A F. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830–1835
   PubMed Web of Science ®Google Scholar
• Nestler E J. Molecular neurobiology of addiction. Am J Addict 2001; 10: 201–217
   PubMed Web of Science ®Google Scholar
• Nestler E J. Is there a common molecular pathway for addiction?. Nat Neurosci 2005; 8: 1445–1449
   PubMed Web of Science ®Google Scholar
• Newton T F, Ling W, Kalechstein A D, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 2001; 102: 227–233
   PubMed Web of Science ®Google Scholar
• O'Brien C P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005; 162: 1423–1431
   PubMed Web of Science ®Google Scholar
• O'Malley S S, Krishnan-Sarin S, Farren C, Sinha R, Kreek M J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 2002; 160: 19–29
   PubMed Web of Science ®Google Scholar
• Oslin D W, Berrettini W H, O'Brien C P. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol 2006; 11: 397–403
   PubMed Web of Science ®Google Scholar
• Paez J G, Janne P A, Lee J C, Tracy S, Greulich H, Gabriel S, Herman P, Kaye F J, Lindeman N, Boggon T J, Naoki K, Sasaki H, Fujii Y, Eck M J, Sellers W R, Johnson B E, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500
   PubMed Web of Science ®Google Scholar
• Pérez de los Cobos J, Siñol N, Trujols J, del Río E, Bañuls E, Luquero E, Menoyo A, Queraltó J M, Baiget M, Alvarez E. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007; 89: 190–194
   PubMed Web of Science ®Google Scholar
• Pessiglione M, Seymour B, Flandin G, Dolan R J, Frith C D. Dopamine-dependent prediction errors underpin reward-seeking behavior in humans. Nature 2006; 442: 1042–1045
   PubMed Web of Science ®Google Scholar
• Pierce R C, Kalivas P W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 1997; 25: 192–216
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Arbuckle J B, Bowman C E, Brunner M, Burns D K, Delrieu O, Dix L P, Twomey J A, Stern R S. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8: 1661–1691
   PubMed Web of Science ®Google Scholar
• Ray L A, Hutchison K E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28: 1789–1795
   PubMed Web of Science ®Google Scholar
• Ray L A, Hutchison K E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 2007; 64: 1069–1077
   PubMed Web of Science ®Google Scholar
• Roberts A J, McDonald J S, Heyser C J, Kieffer B L, Matthes H W, Koob G F, Gold L H. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293: 1002–1008
   PubMed Web of Science ®Google Scholar
• Robinson T E, Berridge K C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247–291
   PubMed Web of Science ®Google Scholar
• Robinson T E, Berridge K C. Addiction. Annu Rev Psychol 2003; 54: 75–114
   Web of Science ®Google Scholar
• Rocha J C, Cheng C, Liu W, Kishi S, Das S, Cook E H, Sandlund J T, Rubnitz J, Ribeiro R, Campana D, Pui C H, Evans W E, Relling M V. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105
   Web of Science ®Google Scholar
• Rogers J F, Nafziger A N, Bertino J SJ. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113: 746–750
   PubMed Web of Science ®Google Scholar
• Romach M K, Glue P, Kampman K, Kaplan H L, Somer G R, Poole S, Clarke L, Coffin V, Cornish J, O'Brien C P, Sellers E M. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 1999; 56: 1101–1106
   PubMed Web of Science ®Google Scholar
• Ron D, Jurd R. The “ups and downs” of signaling cascades in addiction. Sci STKE 2005; 309: 1–16
   Google Scholar
• Roses A D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5: 645–656
   PubMed Web of Science ®Google Scholar
• Ross J R, Rutter D, Welsh K, Joel S P, Goller K, Wells A U, Du Bois R, Riley J. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5: 324–336
   PubMed Web of Science ®Google Scholar
• Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt L G, Hoehe M R. Human mu-opioid receptor variation and alcohol dependence. Alcohol Clin Exp Res 1998; 22: 2108–2110
   PubMed Web of Science ®Google Scholar
• Schinka J A, Town T, Abdullah L, Crawford F C, Ordorica P I, Francis E, Hughes P, Graves A B, Mortimer J A, Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 2002; 7: 224–228
   PubMed Web of Science ®Google Scholar
• Schuckit M A, Gold E, Risch C. Plasma cortisol levels following ethanol in sons of alcoholics and controls. Arch Gen Psychiatry 1987; 44: 942–945
   PubMed Web of Science ®Google Scholar
• Scordo M G, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3: 201–218
   PubMed Web of Science ®Google Scholar
• Sherer M A, Kumor K M, Jaffe J H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 1989; 27: 117–125
   PubMed Web of Science ®Google Scholar
• Simard C, Drolet B, Yang P RBK, Roden D M. Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther 2005; 77: 138–144
   PubMed Web of Science ®Google Scholar
• Simonato M. The neurochemistry of morphine addiction in the neocortex. Trends Pharmacol Sci 1996; 17: 410–415
   PubMed Web of Science ®Google Scholar
• Smolka M, Sander T, Schmidt L G, Samochowiec J, Rommelspacher H, Gscheidel N, Wendel B, Hoehe M R. mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 1999; 24: 629–638
   PubMed Web of Science ®Google Scholar
• Somogyi A A, Barratt D T, Coller J K. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429–444
   PubMed Web of Science ®Google Scholar
• Sora I, Elmer G, Funada M, Pieper J, Li X F, Hall F S, Uhl G R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001; 25: 41–54
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267–280
   PubMed Web of Science ®Google Scholar
• Stamer U M, Bayerer B, Stuber F. Genetics and variability in opioid responses. Eur J Pain 2005; 9: 101–104
   PubMed Web of Science ®Google Scholar
• Sweeney B P. Pharmacogenomics and anaesthesia: explaining the variability in response to opiates. Eur J Anaesthesiol 2007; 23: 209–212
   Web of Science ®Google Scholar
• Swift R M, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151: 1463–1467
   PubMed Web of Science ®Google Scholar
• Tantisira K G, Hwang E S, Raby B A, Silverman E S, Lake S L, Richter B G, Peng S L, Drazen J M, Glimcher L H, Weiss S T. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004; 101: 18099–18104
   PubMed Web of Science ®Google Scholar
• Thaker G K. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007; 11: 1189–1206
   PubMed Web of Science ®Google Scholar
• Tiseo P J, Thaler H T, Lapin J, Inturrisi C E, Portenoy R K, Foley K M. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47–54
   PubMed Web of Science ®Google Scholar
• Tsankova N, Renthal W, Kumar A, Nestler E J. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355–367
   PubMed Web of Science ®Google Scholar
• Tyndale R F, Droll K P, Sellers E M. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375–379
   PubMedGoogle Scholar
• vandenwildenberg E, Wiers R W, Dessers J, Janssen R G, Lambrichs E H, Smeets H J, vanbreukelen G J. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007; 31: 1–10
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wang G J, Fowler J S, Thanos P, Logan J, Gatley S J, Gifford A, Ding Y S, Wong C, Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replications study. Synapse 2002; 46: 79–82
   PubMed Web of Science ®Google Scholar
• Volkow N D, Wise R A. How can drug addiction help us understand obesity?. Nat Neurosci 2005; 8: 555–560
   PubMed Web of Science ®Google Scholar
• Vollm B A, de Araujo I E, Cowen P J, Rolls E T, Kringelbach M L, Smith K A, Jessard P, Heal R J, Matthews P M. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 2004; 29: 1715–1722
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Alterman A I, Hayashida M, O'Brien C P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–880
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Davis M A, Olgin J E. Naltrexone blocks the post-shock increase in ethanol consumption. Life Sci 1986; 38: 841–847
   PubMed Web of Science ®Google Scholar
• Volpicelli J R, Watson N T, King A C, Sherman C E, O'Brien C P. Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry 1995; 152: 613–615
   PubMed Web of Science ®Google Scholar
• Waltman C, Blevins L SJ, Boyd G, Wand G S. The effects of mild ethanol intoxication on the hypothalamic-pituitary-adrenal axis in nonalcoholic men. J Clin Endocrinol Metab 1993; 77: 518–522
   PubMed Web of Science ®Google Scholar
• Wand G S, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A. The mu-receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26: 106–114
   PubMed Web of Science ®Google Scholar
• Wang G J, Volkow N D, Fowler J S, Logan J, Abumrad N N, Hitzemann R J, Pappas N S, Pascani K. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropharmacology 1997; 16: 174–182
   Google Scholar
• Wang G J, Yang J, Volkow N D, Telang F, Ma Y, Zhu W, Wong C T, Tomasi D, Thanos P K, Fowler J S. Gastric stimulation in obese subjects activates the hippocampus and other regions involved in brain reward circuitry. Proc Natl Acad Sci U S A 2006; 103: 15641–15645
   PubMed Web of Science ®Google Scholar
• White F J. Synaptic regulation of mesocorticolimbic dopamine neurons. Annu Rev Neurosci 1996; 19: 405–436
   PubMed Web of Science ®Google Scholar
• Wiesbeck G A, Mauerer C, Thome J, Jakob F, Boening J. Alcohol dependence, family history, and D2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Drug Alcohol Depend 1995; 40: 49–53
   PubMed Web of Science ®Google Scholar
• Wise R A. Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5: 483–494
   PubMed Web of Science ®Google Scholar
• Wong M L, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor R M, McCann S M, Licinio J. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124–15129
   PubMed Web of Science ®Google Scholar
• Yacubian J, Sommer T, Schroeder K, Glascher J, Braus D F, Buchel C. Subregions of the ventral striatum show preferential coding of reward magnitude and probability. Neuroimage 2007; 38: 557–563
   PubMed Web of Science ®Google Scholar
• Yang C W, Hung S I, Juo C G, Lin Y P, Fang W H, Lu I H, Chen S T, Chen Y T. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 870–877
   PubMed Web of Science ®Google Scholar
• Zalewska-Kaszubska J, Czarnecka E. Deficit in beta-endorphin peptide and tendency to alcohol abuse. Peptides 2005; 26: 701–705
   PubMed Web of Science ®Google Scholar
• Zhang D, Shao C, Shao M, Yan P, Wang Y, Liu Y, Liu W, Lin T, Xie Y, Zhao Y, Lu D, Li Y, Jin L. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol Psychiatry 2007; 61: 1244–1251
   PubMed Web of Science ®Google Scholar
• Zhang H, Luo X, Kranzler H R, Lappalainen J, Yang B Z, Krupitsky E, Zvartau E, Gelernter J. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 2006; 15: 807–819
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang D, Johnson A D, Papp A C, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280: 32618–32624
   PubMed Web of Science ®Google Scholar
• Zubieta J K, Heitzeg M M, Smith Y R, Bueller J A, Xu K, Xu Y, Koeppe R A, Stohler C S, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter reponses to a pain stressor. Science 2003; 299: 1240–1243
   PubMed Web of Science ®Google Scholar